For dietary management of GI dysfunction
enterade® is a medical food for the dietary management of gastrointestinal dysfunction, benefitting individuals suffering from occasional diarrhea, cramping, dehydration, nausea and malnutrition. enterade is an ideal solution for patients undergoing treatment for cancer as well as for those diagnosed with conditions such as IBD (Crohn’s and colitis), IBS, celiac, etc. Powered by proprietary Amino Acid-Coupled Transport Technology (A2CT), enterade uses no sugar to help effectively address digestive discomforts for improved quality of life.
- Hydrates, rebuilds and protects the gut lining
enterade helps rebuild damaged GI structure plus provides a protective gut lining barrier that supports healthy immune function.
- Increases fluid retention while reducing stool frequency and stool volume associated with diarrhea
Clinical studies have shown enterade’s patented blend of amino acids and electrolytes offer better nutrient retention in contrast to glucose-based alternatives. The result is triple compartment, whole-body hydration, essential to healthy gut function and enhanced nutrient absorption and retention.
- Ideal for oncology patients as well as sufferers of Crohn’s, IBD, colitis
enterade has been shown to effectively reduce the negative side effects of chemotherapy and radiation treatment and restore healthy GI function for numerous conditions.
enterade is Entrinsic Health Solutions’ flagship product and was used in the original research partially sponsored by NASA and conducted by physicians at the University of Florida. Entrinsic Health Solutions has partnered with 21st Century Oncology, a premier provider of radiation therapy and integrated cancer treatments, to confirm the efficacy of enterade in oncology patients. Completion of these studies are expected by Q2 2016.
Entrinsic Health Solutions is also finalizing details of a study at Dana Farber Cancer Institute in partnership with Brigham and Women’s Hospital to investigate the effectiveness of enterade vs standard of care in reducing diarrhea with melphalan conditioning patients undergoing autologous stem-cell transplantation for Multiple Myeloma or Non-Hodgkin Lymphoma.
Lastly, Entrinsic Health Solutions is finalizing details of a randomized two-arm study at the Baylor College of Medicine Dan L. Duncan Cancer Center in collaboration with Baylor University and Duke University to compare the rate of CTCAE (version 4.03) grade 2+ diarrhea with enterade vs placebo in patients undergoing concurrent chemotherapy and pelvic irradiation for gastrointestinal or gynecologic malignancies.